Table 3.
Meta-analysis of grade 3–4 adverse events*
| Adverse event | No. of trials |
Events in
IMiD arm |
Events in control arm | RR (95% CI) | P |
|---|---|---|---|---|---|
| Vascular events | 10 | 123/1958 | 54/2157 | 2.52 (1.41 to 4.52) | .002 |
| Peripheral neuropathy | 6 | 53/1419 | 28/1610 | 2.27 (1.35 to 3.84) | .002 |
| Neutropenia | 9 | 484/1894 | 255/2090 | 2.73 (1.63 to 4.55) | <.001 |
| Thrombocytopenia | 10 | 159/1886 | 89/2084 | 2.14 (1.34 to 3.40) | .001 |
| Anemia | 10 | 149/1955 | 114/2153 | 1.43 (1.13 to 1.80) | .003 |
| Infection | 9 | 297/1654 | 223/1863 | 1.64 (1.40 to 1.92) | <.001 |
| Fatigue | 10 | 130/1969 | 106/2166 | 1.48 (1.08 to 2.03) | .016 |
| Constipation | 7 | 36/1502 | 18/1692 | 1.82 (1.03 to 3.21) | .039 |
| Second primary malignancies | 7 | 93/1593 | 72/1589 | 1.33 (0.81 to 2.19) | .257 |
* All statistical tests were two-sided. CI = confidence interval; IMiD = immunomodulatory drug; RR = risk ratio.